Premium
The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
Author(s) -
Slevin ML,
Piall EM,
Aherne GW,
Johnston A,
Sweatman MC,
Lister TA
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb01258.x
Subject(s) - bolus (digestion) , pharmacokinetics , medicine , intravenous bolus , subcutaneous injection , cytosine , anesthesia , cytarabine , pharmacology , chemotherapy , chemistry , dna , biochemistry
1 The pharmacokinetics of subcutaneous cytosine arabinoside were compared with bolus intravenous injection and intravenous infusion in five patients with acute myelogenous leukaemia. 2 Subcutaneous cytosine arabinoside was rapidly absorbed and then declined biexponentially with initial and terminal half‐lives similar to intravenous bolus injection. 3 Cytosine arabinoside levels declined rapidly after intravenous bolus and subcutaneous bolus injection, and fell below steady state infusion levels after a mean time of 40 min (intravenous bolus) and 100 min (subcutaneous injection).